awmsg logo



olaratumab (Lartruvo®)


Reference No. 2769

Excluded date:
14/10/2016


Appraisal information

olaratumab (Lartruvo®) concentrate for solution for infusion


Company: Eli Lilly & Co Ltd
BNF category: Malignant disease and immunosupression
   
   
Submission Type: Unspecified
Status: Excluded

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

Indication

In combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin

AWMSG advice

Product meets AWMSG exclusion criteria due to NICE appraisal